Perrigo Company plc (NYSE: PRGO) is a leading global provider of 'Quality, Affordable Self-Care Products™'. With a mission to make lives better by bringing quality, affordable self-care products that consumers trust everywhere they are sold, Perrigo focuses on consumer-facing businesses. The company operates in several segments, including Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). Perrigo is dedicated to enhancing individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.
Serves as the company's official corporate and legal headquarters, supporting global governance, financial reporting, and strategic oversight. It's key to Perrigo's international corporate structure.
The Sharp Building is a modern, LEED Gold certified office building in a prominent business district of Dublin, reflecting a commitment to sustainability and a contemporary corporate image.
The Dublin headquarters fosters a professional, internationally-focused environment centered on corporate governance, strategic financial management, and global operations oversight.
The Dublin headquarters is significant for Perrigo's status as a global company, facilitating its international business operations and financial structuring. It underscores the company's evolution into a global entity.
Perrigo supports a wide range of functions globally, reflecting its status as a leading provider of self-care products. These functions include research and development (R&D) for new products and formulations, extensive manufacturing capabilities across multiple countries, quality control and assurance, regulatory affairs, sales and marketing operations tailored to diverse international markets, and robust supply chain and distribution networks to ensure products reach consumers worldwide. Key regions include North America, Europe, and other international markets.
The Sharp Building, Hogan Place
Dublin
Dublin 2
Ireland
Address: 40 Fuller Ave NE, Grand Rapids, MI 49503, USA
To lead and support the development, manufacturing, and distribution of consumer self-care products throughout North America, leveraging its proximity to key markets and historical company roots in Michigan.
Address: Mivtza Kadesh St 38, Yeruham, Israel
To develop and manufacture high-quality APIs and finished dosage forms, supporting Perrigo's global pharmaceutical and self-care product portfolio, leveraging Israel's strong pharmaceutical R&D ecosystem.
Address: 515 Eastern Ave, Allegan, MI 49010, USA
To support large-scale manufacturing and distribution for the North American market, drawing on decades of operational expertise at this location.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Perrigo Company plc' leadership includes:
Perrigo Company plc has been backed by several prominent investors over the years, including:
Perrigo has experienced significant executive team renewal in the past year, including a new CEO and CFO, alongside key appointments in operations, scientific affairs, commercial leadership for the Americas, and human resources, reflecting a period of strategic leadership transition.
Discover the tools Perrigo Company plc uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Perrigo Company plc commonly uses standard corporate email formats, typically combining employee names with the company domain 'perrigo.com'. The most prevalent formats are firstname.lastname and firstinitiallastname.
[first].[last]@perrigo.com or [first_initial][last]@perrigo.com
Format
jane.doe@perrigo.com
Example
85%
Success rate
Perrigo Investor Relations • May 8, 2024
Perrigo announced its Q1 2024 financial results, reporting net sales of $1.1 billion. The company highlighted strong performance in its Consumer Self-Care Americas (CSCA) segment and reaffirmed its full-year 2024 organic net sales and adjusted diluted EPS guidance. CEO Patrick Lockwood-Taylor emphasized progress on strategic initiatives and portfolio transformation....more
Perrigo Newsroom • July 13, 2023
Perrigo received landmark FDA approval for Opill®, the first-ever daily oral contraceptive to be available over-the-counter in the United States. This approval marks a significant milestone in women's health, expanding access to contraception....more
Perrigo Newsroom • March 26, 2024
Perrigo announced that Opill®, the first daily birth control pill available without a prescription in the U.S., is now shipping to major retailers and pharmacies and will be available on shelves nationwide and online. This follows the FDA approval in July 2023....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Perrigo Company plc, are just a search away.